Clinical outcomes in ER+ HER2 -node-positive breast cancer patients who were treated according to the Recurrence Score results: evidence from a large prospectively designed registry
Salomon M. Stemmer(Tel Aviv University), Noa Ben-Baruch(Kaplan Medical Center), Debbie McCullough(Genomic Health (United States)), Georgeta Fried(Roche (Switzerland)), Lior Soussan‐Gutman(Teva Pharmaceuticals (Israel)), Nicky Liebermann(Clalit Health Services), Steven Shak(Genomic Health (United States)), Shulamith Rizel(Rabin Medical Center), Avital Bareket‐Samish, David Geffen(Ben-Gurion University of the Negev), Tamar Peretz(Hadassah Medical Center), Christer Svedman(Genomic Health (United States)), Kevin Isaacs(Emek Medical Center), Mariana Steiner(Haifa Medical Center), Bella Nisenbaum(Meir Medical Center), Ora Rosengarten(Sheba Medical Center)
Cited by 87
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
|Gynecologic Oncology|2015|301
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer
|JAMA Oncology|2021|291
ChIP-seq of plasma cell-free nucleosomes identifies gene expression programs of the cells of origin
|Nature Biotechnology|2021|169